抄録
The purpose of this study was to determine whether the healing process in membrane-protected bone defects could be accelerated dose-dependently by basic fibroblast growth factor(FGF-2)using a slow drug-release pellet. Mandibular premolars at both sides were extracted, and bone defects(8×5×5‐7mm)were made in the edentulous area, in beagle dogs. FGF‐2 was administered using specially made collagen pellets. The defects were assigned to be treated in one of four ways:(1)In the FGF (0.1)group, a collagen minipellet containing 0.1μg FGF‐2 was administered;(2)in the FGF(1.0)group, a collagen minipellet containing 1.0μg FGF‐2 was administered;(3)in the Placebo group, a collagen minipellet without FGF‐2 was administered;(4)in the Control group, nothing was administered in the bone defect. All defects were filled up with blood, covered with e-PTFE membranes, and muco-periosteal flaps were then tightly sutured.Bone regeneration was evaluated 10 weeks after the operation by decalcified sections. Histologically,in the FGF(0.1)group, regenerated bone was seen widely in the inner space of membrane-protected defect. In contrast, the bone regeneration seen in the FGF(1.0)group was only adjacent to the border of defect. Morphometric analysis showed that the regenerated bone area ratio of the FGF (0.1)group(42.3±6.6%)was significantly higher than any other groups;on the other hand,the FGF(1.0)group(7.0±1.7%)was significantly higher than any other group (p＜0.05).These results suggest that the effect of controlled local administration of FGF‐2 is biphasic, in that higher doses may be inhibitory, so that we should control the optimal dose in clinical trials.
